Alnylam Pharma (ALNY) Makes Two Key Executive Appointments
- Wall Street surges to new highs; transports set record
- lululemon athletica (LULU) Tops Q3 EPS by 4c; Adj.-Comps Outpaced Views
- Abbott (ABT) Files Complaint to Terminate Alere (ALR) Acquisition
- Costco Wholesale (COST) Tops Q1 EPS by 5c; Comps Up 1%, 2% Ex-Gas
- After-Hours Stock Movers 12/07: (VYGR) (LULU) (HRB( Higher; (OHRP) (VRNT) (CMTL) Lower (more...)
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced two key appointments to its senior leadership team, expanding the breadth of talent and experience as the company prepares for commercialization of its pipeline and global expansion. Dr. Yvonne Greenstreet has joined as Executive Vice President, Chief Operating Officer, and Dr. Emmanuel Dulac as Senior Vice President, Chief Commercial Officer. Both Drs. Greenstreet and Dulac offer decades of life science experience in drug development and successfully launching medicines to the market in areas of unmet needs. In addition, both have worked in global capacities and have supported execution on strategies involving substantial organizational growth. Barry Greene will continue to serve as the Company’s President.
“With our rapid pipeline growth and maturity toward commercial stages, we’re focused on building our team to achieve our Alnylam 2020 goals. In this regard, the appointments of Yvonne and Emmanuel significantly bolster the depth of product experience and commercial expertise in our growing organization,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “I’m confident that their insight and leadership will help us realize our mission of building a top-tier biopharmaceutical company founded on RNAi and speed the path of bringing potentially life changing new therapies to patients through innovative drug development, commercial, and patient access strategies.”
Dr. Greenstreet will report to John Maraganore, and will have responsibility for leading the company’s multi-disciplinary product teams from early development through and during commercialization. In this capacity Yvonne will have responsibility for the global General Managers (currently in place for ATTR programs, fitusiran, and ALN-CC5), Program Leaders, and the Program Management team, which are all focused on progressing development pipeline programs through to launch and commercialization. Additionally, she will be responsible for leading the Alliance Management team primarily focused on our partnership with Sanofi Genzyme.
“It’s a pleasure to join the team at Alnylam at such an important time in the company’s evolution, where RNAi therapeutics are advancing toward commercial stages,” said Dr. Greenstreet. “Alnylam’s pipeline is one of the most exciting in the industry, and I’m thrilled to be part of a team pioneering new medicines to meet unmet needs for patients. This is a vitally important mission where I believe I can add significant value.”
Dr. Greenstreet brings 25 years of global experience in the pharmaceutical industry, where she has been in senior roles in research and development, strategy, and portfolio management, and has successfully led product development and commercialization teams in a wide range of therapy areas, bringing new medicines to patients. Dr. Greenstreet was previously Senior Vice President and Head of Medicines Development at Pfizer, with accountability for a portfolio that included the immuno-inflammation, vaccines, specialty neuroscience, and rare disease areas. Prior to Pfizer, she held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President and Chief of Strategy for Research and Development, Senior Vice President for Medicines Development, and Chief Medical Officer for Europe. Dr. Greenstreet holds a Bachelor of Medicine, Bachelor of Surgery from the University of Leeds, UK and Master of Business Administration (MBA) from INSEAD, France. She serves as an advisor and board member for several public companies and also serves on the Scientific Advisory Committee for the Bill and Melinda Gates Foundation.
Dr. Dulac will report to Barry Greene, and will be responsible for establishing Alnylam’s global commercial footprint. He will lead the development of the global commercial expertise area, building global commercial capabilities, including support of patients post product launch, and building the U.S. commercial operations.
“I feel fortunate to be joining Alnylam at a time when we have the opportunity to develop and shape our commercial strategies for a ground breaking new approach to treating disease. RNAi therapeutics have now passed the proof of concept stage and have the potential to profoundly transform patients’ lives. It gives us the potential to target many unserved diseases with an extremely precise medicine and an uncommonly long duration of activity. I feel privileged to have been entrusted to build and lead a top-tier organization that will attract the best talent in the industry and bring these truly differentiated medicines to patients,” said Dr. Dulac.
Dr. Dulac brings to Alnylam more than 20 years of international experience in the biotech and pharmaceutical industry. He joins the company from Shire, where he was Senior Vice President, Head of the Rare Disease Business Unit. Prior to Shire, Emmanuel held various roles of increasing responsibility at Sanofi, Abbott, and Novartis in global, regional and local functions. During his career, he successfully launched six brands, led two blockbuster drugs globally, and built large sales organizations, innovative patient services, and strong marketing and market access teams. He graduated from the University of Paris XI with a Doctorate in Pharmacology (PharmD, Ph.D.) and completed an MBA from the ESSEC School in Paris.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corvex Management Cuts Signet Jewelers (SIG) Stake in Half
- NV5 Global (NVEE) Announces Acquisition of CivilSource
- Shutterfly (SFLY) Adds Two New Directors
Create E-mail Alert Related CategoriesCorporate News, Management Changes, Management Comments
Related EntitiesGenzyme/Sanofi-Aventis, Bill & Melinda Gates Foundation Trust, AdCom
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!